speb/financial-data huggingface dataset:
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 522600000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 2290600000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -693900000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 339500000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 916700000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 616000000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 2283200000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -275400000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 574600000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 41400000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Change In Inventory: 9200000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Change In Payable: 406700000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Change In Receivables: 138700000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: 554600000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 93400000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Common Stock: 916700000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 4777600000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 29700000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 7809600000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Current Assets: 3079800000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 16800000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 16800000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 1654200000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 21600000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Depreciation: 400800000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 400800000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 400800000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 394600000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 91673000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Diluted EPS: 13.52
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 1239600000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 13500000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — EBIT: 1671700000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — EBITDA: 2072500000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — End Cash Position: 616000000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -323800000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 1307600000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: 11700000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 117500000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 10500000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 687100000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 5617000000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Gross Profit: 4231000000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Interest Expense: 10600000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 10600000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Interest Income: 168900000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 168900000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -10500000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Interest Paid Cfo: -100000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 123100000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Inventory: 75300000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 4777600000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -1584300000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 605200000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 322700000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 322700000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 271900000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 711300000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Net Income: 1239600000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 1239600000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 1239600000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 1239600000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 1239600000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 1661100000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 1239600000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Net Interest Income: 128300000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -1013500000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: 128300000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Net PPE: 3488600000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -693900000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 4767100000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 197200000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 271900000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 48200000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 2084200000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Normalized Income: 1248331154.05
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 2001500000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Operating Income: 1640800000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Operating Revenue: 12040600000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 91673000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 111500000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 126000000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 3860900000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 10500000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 4500000.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: -158300000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 51700000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: 8800000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 168900000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 1381500000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Other Payable: 53600000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Other Properties: 2585400000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 1667200000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Other Special Charges: 11700000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Payables: 1401800000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 21600000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 111500000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Pretax Income: 1661100000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -693900000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 70800000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 7809600000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 400800000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 23500000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 23500000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 25800000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 3555200000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 1042200000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 1159700000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Share Issued: 91673000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Special Income Charges: -11700000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 4777600000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 4767100000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: -2968845.95
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Tax Provision: 421500000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.25
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 0.00
INDRAMEDCO.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -468300000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Total Assets: 7232400000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 4777600000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Total Debt: 339500000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 4777600000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Total Expenses: 10399800000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 2454800000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 4152600000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 800600000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 30000000.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 5800000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Total Unusual Items: -11700000.00
INDRAMEDCO.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 0.00
INDRAMEDCO.NS balance_sheet (annual, 2024-03-31) — Working Capital: 1425600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 1325100000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 751400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 327400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 916700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 667700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 3174100000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 916700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 5244300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 2500000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 4196600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 17500000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 17500000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 2031800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 39500000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 8300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 3407900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 78600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 5244300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 410500000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 309900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 309900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 279100000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 3407900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 5236000000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 189200000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 91673000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 140900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 646400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 4327600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 39900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 3405400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 2506400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Payables: 1325100000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 91673000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 5244300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 5236000000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 51600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 8063200000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 5244300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 327400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 5244300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 2818900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 3866600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 787100000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 0.00
INDRAMEDCO.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 2164800000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 695500000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 3249300000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 91648045.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 3.58
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 2144000000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 112100000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 112100000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 91648045.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 3.58
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 328100000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — EBIT: 461100000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — EBITDA: 573200000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 1105300000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 15800000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 15800000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Net Income: 328100000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 328100000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 328100000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 328100000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 328100000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 328100000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -15800000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -15800000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 573200000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 328100000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Operating Income: 409800000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 3249300000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 51300000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 583400000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 445300000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 2144000000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 112100000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 117200000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.26
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 2839500000.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — +Operating Expense: 2936800000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 701900000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — +Total Revenue: 13563600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 3337500000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 1225400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 1225400000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 754500000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 754500000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -2275300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -2275300000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 0.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -113000000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -113000000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Amortization: 4600000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 4600000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 549200000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 549200000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 91679954.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 91744966.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Basic EPS: 17.56
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 4.47
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 616000000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 2300300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 2300300000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -363300000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 327600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 327600000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 916700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 916700000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 614800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 614800000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 3279100000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 3279100000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -407300000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 571100000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 571100000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 43700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 43700000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Change In Inventory: 5400000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Change In Payable: -49800000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -193600000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -238000000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -1200000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Common Stock: 916700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 916700000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 5966800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 5966800000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 331700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 331700000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 8627400000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 2131500000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Current Assets: 4311300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 4311300000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 22200000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 22200000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 22200000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 22200000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 1787100000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 1787100000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 87400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 87400000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Depreciation: 443300000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 443300000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 443300000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 109100000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 443300000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 109100000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 91679954.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 91744966.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Diluted EPS: 17.56
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 4.47
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 1609900000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 410100000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 18800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 18800000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — EBIT: 2225900000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — EBIT: 567600000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — EBITDA: 2669200000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — EBITDA: 676700000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — End Cash Position: 614800000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -458800000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 1204200000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: 5200000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 5900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 5900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 867500000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 5881700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 5881700000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Gross Profit: 4936200000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 1206000000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Interest Expense: 62700000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 14900000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 62700000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 14900000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Interest Income: 226500000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 226500000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -30200000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Interest Paid Cfo: -100000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 171700000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Inventory: 69900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 69900000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 5966800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 5966800000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -1109900000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 549200000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 549200000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 305400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 305400000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 305400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 305400000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 294700000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 294700000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 651500000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 651500000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Net Income: 1609900000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Net Income: 410100000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 1609900000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 410100000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 1609900000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 410100000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1609900000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 410100000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1609900000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 410100000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 2163200000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 1609900000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 410100000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Net Interest Income: -62700000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -14900000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 0.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -62700000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -14900000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Net PPE: 3606400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 3606400000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -363300000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 5960900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 5960900000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 153900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 153900000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 294700000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 42900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 42900000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 2669200000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 676700000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Normalized Income: 1609900000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 410100000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 1567500000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Operating Income: 1999400000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Operating Income: 504100000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Operating Revenue: 13563600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 3337500000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 91673000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 91673000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 166000000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 166000000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 110500000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 110500000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 5050100000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 5050100000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 5900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 5900000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 5000000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 5000000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -196300000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 27900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 27900000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 8300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 8300000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 226500000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 63500000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 2493500000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 592800000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Other Payable: 241800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 241800000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Other Properties: 2598200000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 2598200000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 2664300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 2664300000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Payables: 1486000000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Payables: 1486000000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 87400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 87400000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 166000000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 166000000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Pretax Income: 2163200000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 552700000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -363300000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 64900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 64900000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 8627400000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 2131500000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 443300000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 109100000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 22900000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 22900000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 31600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 31600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 4752600000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 853600000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 984000000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Share Issued: 91673000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 91673000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Special Income Charges: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 5966800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 5966800000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 5960900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 5960900000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Tax Provision: 553300000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 142600000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.26
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.26
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 10200000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 10200000.00
INDRAMEDCO.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -609800000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Total Assets: 8516200000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 8516200000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 5966800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 5966800000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Total Debt: 327600000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 327600000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 5966800000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 5966800000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Total Expenses: 11564200000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 2833400000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 2549400000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 2549400000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 4204900000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 4204900000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 762300000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 762300000.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 32400000.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 0.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 0.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
INDRAMEDCO.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
INDRAMEDCO.NS balance_sheet (annual, 2025-03-31) — Working Capital: 2524200000.00
INDRAMEDCO.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 2524200000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 764600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 3650600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 91729055.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 5.61
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 2256300000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 101800000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 101800000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 91729055.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 5.61
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 514600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — EBIT: 698700000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — EBITDA: 800500000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 1394300000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 15600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 15600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Net Income: 514600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 514600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 514600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 514600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 514600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 514600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -15600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -15600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 800500000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 514600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Operating Income: 629700000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 3650600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 69000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 662800000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 683100000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 2256300000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 101800000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 168500000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.25
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 3020900000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 868100000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 3716100000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 91722595.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 4.47
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 2341000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 112500000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 112500000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 91722595.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 4.47
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 410000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — EBIT: 578500000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — EBITDA: 691000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 1375100000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 14600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 14600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Net Income: 410000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 410000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 410000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 410000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 410000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 410000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -14600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -14600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 691000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 410000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Operating Income: 507000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 3716100000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 71500000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 755600000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 563900000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 2341000000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 112500000.00
INDRAMEDCO.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: 0.00